In patients with atopic dermatitis, when and how should allergen-specific immunotherapy be considered?

Allergen-Specific Immunotherapy in Atopic Dermatitis

Allergen-specific immunotherapy (AIT) should be considered as an adjunctive treatment for atopic dermatitis patients who have documented aeroallergen sensitization (particularly to house dust mites) and whose disease remains uncontrolled despite optimal topical therapy. This is a potential indication rather than a routine recommendation, as the evidence remains limited compared to its established role in allergic rhinitis and asthma 1.

When to Consider AIT

Consider AIT specifically when:

• Documented IgE sensitization to clinically relevant aeroallergens (especially house dust mites) is present via specific IgE testing or skin prick testing 1
• Moderate-to-severe AD persists despite appropriate topical anti-inflammatory therapy 2
• Concomitant allergic rhinitis or asthma exists, as AIT has proven efficacy for these conditions 1
• Patient demonstrates clear temporal relationship between allergen exposure and AD flares
• Patient preference favors disease-modifying therapy over long-term pharmacotherapy 1

The AAD guidelines classify AIT as a "potential indication" for AD with aeroallergen sensitivity, not a standard recommendation 2. This reflects the limited and conflicting evidence base compared to established AD treatments.

Evidence Quality and Limitations

The evidence supporting AIT in AD is considerably weaker than for respiratory allergies:

• A 2013 meta-analysis of 8 RCTs (385 subjects) showed moderate benefit (OR 5.35), with particularly positive results for subcutaneous immunotherapy (OR 4.27) and long-term treatment >1 year (OR 6.42) 3
• However, significant heterogeneity exists across studies in terms of allergens used, administration routes, patient populations, and outcome measures 3, 4
• More recent studies (2018-2021) show 49-54% reduction in SCORAD scores with house dust mite immunotherapy, with better responses in mild-to-moderate disease 5, 6
• Sublingual immunotherapy for dust mites showed only modest results requiring 9-12 months to observe benefit, and cannot be routinely recommended 2

Practical Implementation

Route of Administration

Subcutaneous immunotherapy (SCIT) has stronger evidence than sublingual immunotherapy (SLIT) for AD 3. Cluster protocols (accelerated dosing over 8 weeks) have shown efficacy with good tolerability 5.

Expected Timeline

• Minimum 9-12 months of treatment needed before clinical benefit becomes apparent 2
• Optimal results seen with long-term treatment beyond 1 year 3

Monitoring Response

• Use SCORAD index to objectively track disease severity 5, 6
• Atopy patch testing may be more sensitive than skin prick testing for monitoring treatment response 6
• Blood eosinophil counts and total IgE may decrease but are less reliable markers 5

Critical Caveats

Do not use AIT as monotherapy for AD. It should only be considered as adjunctive treatment alongside appropriate topical anti-inflammatory therapy 2. The evidence does not support replacing standard AD management with immunotherapy alone.

Patient selection is crucial. Approximately 28% of patients in clinical studies did not respond to AIT 5. Response rates appear better in:

• Mild-to-moderate disease (53.8% SCORAD reduction) versus severe disease (43.6% reduction) 5
• Patients with clear house dust mite sensitization 5, 6
• Those with concurrent allergic rhinitis 1

Safety profile is generally favorable with no serious adverse reactions reported in recent studies 5, though standard AIT precautions regarding anaphylaxis risk apply.

Current Guideline Consensus

The 2011 allergen immunotherapy practice parameter lists atopic dermatitis with aeroallergen sensitivity as a "potential indication" rather than a standard indication 1. The 2014 AAD guidelines state that injection immunotherapy for dust mite sensitized patients "cannot be routinely recommended" due to limited evidence 2. This conservative stance reflects the need for higher quality, larger-scale RCTs before AIT becomes standard practice for AD.

In clinical practice, reserve AIT for the subset of AD patients with documented aeroallergen sensitization, inadequate response to topical therapy, and willingness to commit to long-term treatment (minimum 1 year). Subcutaneous administration targeting house dust mites has the strongest supporting evidence when this approach is chosen 3, 5.